

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Incorporated in the People's Republic of China)
(Company Registration No.: 91120000103100784F)

ANNOUNCEMENT ON THE EVALUATION REPORT ON THE 2025 ACTION PLAN AND THE ADOPTION OF THE 2026 ACTION PLAN

The board of directors (the “Board”) and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the “Company”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

The Board refers to the announcement made by the Company on 25 August 2025 in relation to the evaluation report on the Company’s 2024 Action Plan for “Quality Improvement, Efficiency Enhancement, and Focus on Shareholder Returns” (2024 年度“提质增效重回报”行动方案), and on the Company’s 2025 Action Plan for “Quality Improvement, Efficiency Enhancement, and Focus on Shareholder Returns” (2025 年度“提质增效重回报”行动方案) (the “**2025 Action Plan**”).

In order to promote the high-quality development of the Company and deliver better returns to its shareholders, the Company has actively implemented the requirements in the *Opinions of the State Council on Further Improving the Quality of Listed Companies* (《关于进一步提高上市公司质量的意见》) and responded to the *Initiative on Launching the Special Action on “Quality Improvement, Efficiency Enhancement, and Focus on Shareholder Returns” for Companies Listed on the Shanghai Stock Exchange* (《关于开展沪市公司“提质增效重回报”专项行动倡议》) issued by the Shanghai Stock Exchange. On this basis, the Company formulated its 2025 Action Plan, pursuant to which the Company has remained focused on its principal business, while enhancing new quality productive forces (新质生产力) and delivering returns to its shareholders. The implementation status of the 2025 Action Plan and the details of the Company’s 2026 Action Plan for “Quality Improvement, Efficiency Enhancement, and Focus on Shareholder Returns” (2026 年度“提质增效重回报”行动方案) are set out in **Appendix A** to this announcement.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
29 April 2026

APPENDIX A

2025 年度“提质增效重回报”行动方案的评估报告暨 2026 年度“提质增效重回报”行动方案

EVALUATION REPORT ON THE 2025 ACTION PLAN FOR “QUALITY IMPROVEMENT, EFFICIENCY ENHANCEMENT, AND FOCUS ON SHAREHOLDER RETURNS”, AND THE ADOPTION OF THE 2026 ACTION PLAN FOR “QUALITY IMPROVEMENT, EFFICIENCY ENHANCEMENT, AND FOCUS ON SHAREHOLDER RETURNS”

为推动公司高质量发展，更好回报投资者，津药达仁堂集团股份有限公司（以下简称“公司”）积极贯彻落实国务院《关于进一步提高上市公司质量的意见》，响应上海证券交易所《关于开展沪市公司“提质增效重回报”专项行动倡议》，制定 2025 年度“提质增效重回报”行动方案，公司持续聚焦主业，提升新质生产力，回报股东。现将公司 2025 年度“提质增效重回报”行动方案落实情况暨 2026 年度“提质增效重回报”行动方案报告如下：

In order to promote the high-quality development of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (the “**Company**”) and deliver better returns to its shareholders, the Company has actively implemented the requirements in the *Opinions of the State Council on Further Improving the Quality of Listed Companies* (《关于进一步提高上市公司质量的意见》) and responded to the *Initiative on Launching the Special Action on “Quality Improvement, Efficiency Enhancement, and Focus on Shareholder Returns” for Companies Listed on the Shanghai Stock Exchange* (《关于开展沪市公司“提质增效重回报”专项行动倡议》) issued by the Shanghai Stock Exchange (the “**SSE**”). On this basis, the Company formulated its 2025 Action Plan for “Quality Improvement, Efficiency Enhancement, and Focus on Shareholder Returns” (2025 年度“提质增效重回报”行动方案) (the “**2025 Action Plan**”), pursuant to which the Company has remained focused on its principal business, while enhancing new quality productive forces (新质生产力) and delivering returns to its shareholders. The implementation status of the 2025 Action Plan and the details of the Company’s 2026 Action Plan for “Quality Improvement, Efficiency Enhancement, and Focus on Shareholder Returns” (2026 年度“提质增效重回报”行动方案) (the “**2026 Action Plan**”) are set out below.

一、聚焦核心工业，聚力核心主业

I. Focusing on Core Industrial Segment and Strengthening Core Products

2025 年，公司持续深耕中成药工业板块，聚力心脑血管、呼吸等核心品类，公司工业端收入同比增长 8.64%。2025 年公司实现营业收入 49.17 亿元，同比下降 32.70%，主要是因为公司完成医药商业板块剥离后，不再确认相关收入。

In 2025, the Company continued to focus on its Chinese patent medicine industrial segment, with emphasis on key product categories including cardiovascular and cerebrovascular products and respiratory products. Revenue from the Company’s industrial segment increased by 8.64% year-on-year. For the financial year ended 31 December 2025 (“**FY2025**”), the Company recorded operating revenue of approximately RMB4.917 billion, representing a year-on-year decrease of 32.70%, mainly due to the completion of the divestment of its pharmaceutical commercial segment, following which revenue from that segment was no longer recognised by the Company.

2026 年，公司将做实 9 大区域分公司，聚焦主品，依托“医疗-零售-电商-C 端”四大板块，落实“存量渠道稳增长，创新营销拓增量”营销思路。拟启动“家庭必备，救在身边——达仁堂速效救心公益行动 3.0 中国家庭必备计划”，筑牢健康“心”防线。

In 2026, the Company will continue to strengthen the operations of its nine (9) regional branches, with a focus on key products. Leveraging its four (4) major channels, namely medical institutions, retail, e-commerce and direct-to-consumer, the Company will implement its marketing strategy of maintaining steady growth through existing channels while driving incremental growth through innovative marketing initiatives. The Company also proposes to launch the “Household Essentials, Emergency Care by Your Side — Da Ren Tang Suxiao Jiuxin Public Welfare Campaign 3.0: China Household Essentials Plan” (家庭必备，救在身边——达仁堂速效救心公益行动 3.0 中国家庭必备计划), with a view to enhancing public awareness of cardiovascular emergency care.

二、提升新质生产力，质胜产业新周期

II. Enhancing New Quality Productive Forces and Promoting Industrial Upgrading

2025 年，公司金银花种植基地通过 GAP 延伸检查，半夏基地获“三无一全”基地认证，完成了 15 个品种溯源基地建设，核心原料溯源覆盖率达 40%；公司建立 46 个高于药典标准的中药材内控标准，编制并发布《津药达仁堂中药材质量标准（2025）》；完成 6 个产品 71 个包装规格的药品说明书适老化改革，实现“数字人视频+电子说明书+语音播报”功能，19 个产品说明书安全性信息科学修订获 CDE 批复，14 个产品取得新加坡国际注册，成功斩获“第六届天津质量奖”正奖。公司成立供应链管理中心，全面推进供应链集约管理；推动数字技术与核心业务融合，提升全链条运营效率与协同能力，与华为云全面深化合作，完成 AI 战略规划，联合申报的“人工智能 + 中医药多场景应用项目”获天津市高质量发展数字化奖补支持，成为该奖项 AI 应用方向的唯一医药企业。

In 2025, the Company's honeysuckle cultivation base passed the extended GAP inspection, its *pinellia ternata* cultivation base obtained the “Three Nos and One Full” (三无一全) base certification, and the Company completed the establishment of traceability bases for 15 varieties, with traceability coverage of core raw materials reaching 40%. The Company established 46 internal control standards for Chinese medicinal materials which are more stringent than the standards prescribed under the Chinese Pharmacopoeia, and prepared and issued the Tianjin Pharmaceutical Da Ren Tang Quality Standards for Chinese Medicinal Materials (2025) (《津药达仁堂中药材质量标准 (2025)》). The Company completed the age-friendly reform of package inserts for 71 packaging specifications across six (6) products, enabling functions such as digital human videos, electronic package inserts and audio playback (数字人视频+电子说明书+语音播报). Scientific revisions to the safety information in the package inserts for 19 products were approved by the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China (国家药品监督管理局药品审评中心), 14 products obtained international registration in Singapore, and the Company was awarded the 6th Tianjin Quality Award (第六届天津质量奖). The Company established a supply chain management centre to promote centralised supply chain management, and continued to promote the integration of digital technologies with its core businesses to enhance operational efficiency and coordination across the entire value chain. The Company further deepened its cooperation with Huawei Cloud and completed its AI strategic planning. The jointly submitted “Artificial Intelligence and Multi-scenario Application in Traditional Chinese Medicine” (人工智能 + 中医药多场景应用项目) project received support under Tianjin's digitalisation incentive and subsidy programme for high-quality development. The Company was the only pharmaceutical enterprise in the AI application category of such award.

2026 年，公司将继续巩固推进前述工作，提升新质生产力，包括拓展溯源基地建设，扩大中成药投料产地鲜切品种规模，从源头夯实成本与质量根基；持续升级“三级质量管控体系”，推进中药说明书标准化修订与质量攻关项目；完善供应链管理流程，提升柔性生产能力等。

In 2026, the Company will continue to consolidate and advance the aforesaid work and enhance new quality productive forces, including by expanding the development of traceability bases, increasing the scale of fresh-cut varieties from places of origin used as raw materials for Chinese patent medicine production, and strengthening the foundation for cost and quality control at source. The Company will also continue to upgrade its “three-tier quality control system” (三级质量管控体系), promote the standardised revision of Chinese medicine package inserts and quality improvement projects, improve supply chain management processes, and enhance flexibility in its production capabilities.

三、重视股东回报，共享发展红利

III. Emphasising Shareholder Returns and Sharing the Benefits of Growth

2025 年 7 月，公司实施了 2024 年度利润分配方案，即每 10 股派发现金红利 12.80 元，合计派发 9.86 亿元。2026 年 2 月，公司实施了 2025 年前三季度利润分配方案，即每 10 股派发现金红利 24.50 元，合计派发 18.87 亿元。

In July 2025, the Company implemented its profit distribution plan for the financial year ended 31 December 2024, pursuant to which a cash dividend of RMB12.80 (inclusive of tax) for every ten (10) shares was distributed, with total cash dividends amounting to approximately RMB986 million. In addition, in respect of the first three quarters of FY2025, a cash dividend of RMB24.50 (inclusive of tax) for every ten (10) shares was paid in February 2026, with total cash dividends amounting to approximately RMB1.887 billion.

未来公司将在持续创造价值的基础上，强化股东回报，遵照证监会《上市公司监管指引第 3 号——上市公司现金分红》，响应证监会有关分红倡议之精神，做好股东回报规划的审议和披露工作，在满足公司营运资本需求，做好资本开支规划的情况下，尽可能以现金分红方式，直接回报股东。目前已制定《达仁堂 2026-2028 年股东回报规划》和《达仁堂 2025 年度利润分配预案》并提交股东大会待审。

Going forward, while continuing to create value, the Company will further enhance shareholder returns. In compliance with the *Regulatory Guideline No. 3 for Listed Companies - Distribution of Cash Dividends by Listed Companies* (《上市公司监管指引第 3 号-上市公司现金分红》) issued by the China Securities Regulatory Commission (the “CSRC”), and in line with the spirit of the dividend-related initiatives of the CSRC, the Company will duly review and disclose its shareholder return plans. Subject to the Company’s working capital requirements and capital expenditure plans, the Company will seek to return value directly to shareholders by way of cash dividends, where practicable. The Company has formulated the Shareholders’ Return Plan for 2026 to 2028, which, together with the Company’s proposed profit distribution plan for FY2025, remains subject to shareholders’ approval at a general meeting of the Company.

四、加强投资者沟通，提升公司透明度

IV. Strengthening Investor Communication and Enhancing Corporate Transparency

2025 年，公司在及时准确公告的基础上，不断提高公告可读性，在定期报告之外，做好《可持续发展报告（ESG 报告）》等多维度信息披露工作，通过图表提高可读性。公司积极组织定期报告业绩说明会，通过投资者热线、互动平台、电子邮箱、现场调研多渠道开展接待沟通；充分利用股东会等契机与股东直面交流，在股东大会休会期间，面向投资者组织参观车间，走进达仁堂博物馆，体验非遗，

中医义诊，品鉴大健康食品等多维度感受达仁堂风貌和中医药文化的各项活动，公司股东反馈良好。在2025年开启了“节气养生——走进达仁堂”系列活动，面向投资者开放实地调研。

In 2025, while ensuring timely and accurate announcements, the Company continued to strengthen its investor relations efforts and improve the readability of its disclosures. In addition to its periodic reports, the Company published its Sustainability Report (ESG Report) and other multi-dimensional disclosures, enhancing readability through charts and graphics. The Company actively organised performance briefings for its periodic reports and engaged with investors through multiple channels, including its investor hotline, interactive platform, email and on-site visits. The Company also made use of opportunities such as general meetings to communicate directly with shareholders. During the adjournment of the general meetings, the Company organised various activities for investors, including visits to its production workshops and the Da Ren Tang Museum, intangible cultural heritage experiences, traditional Chinese medicine consultations and tastings of health food products, allowing investors to gain a broader understanding of Da Ren Tang and traditional Chinese medicine culture. Such activities received positive feedback from the Company's shareholders. In 2025, the Company launched the "Health Preservation by Solar Terms – Visit Da Ren Tang" (节气养生——走进达仁堂) series of investor events, further expanding opportunities for investors to conduct on-site visits.

公司持续关注股东对于公司治理、经营业务的意见建议，股东建议及时反馈至公司管理层和相关部门，发挥股东管理才智。2025年上半年，公司开通了董事长邮箱，也增加了股东参与公司治理的渠道。

The Company has continued to take into account shareholders' views on corporate governance and business operations. Shareholders' suggestions are promptly relayed to the Company's management and relevant departments, with a view to facilitating constructive communication with shareholders. In the first half of 2025, the Company launched the "Chairman's Mailbox", further expanding the channels for shareholders' participation in governance.

2026年，公司将继续做好信息披露，业绩说明会等投资者沟通交流工作。

In 2026, the Company will continue to enhance its information disclosure practices and investor communication activities, including performance briefings.

五、规范治理方面，做好投保工作

V. Strengthening Corporate Governance and Enhancing Investor Protection

2025年，公司根据最新监管法规和政策指引，做好内部制度更新修订和落实，修订《公司章程》和董事会相关委员会议事规则：取消监事会，将监事会职能改为由董事会审计委员会承担，优化治理结构；将董事会战略委员会调整为董事会战略与可持续发展委员会，以加强可持续发展管理，并在公司运营管理层面制定《可持续发展制度》，加强衔接执行。

In 2025, the Company updated and implemented its internal policies in line with the latest regulatory requirements and policy guidelines, including amendments to its Articles of Association. Following such amendments, the Supervisory Committee of the Company was abolished, with the Audit Committee undertaking and exercising the statutory functions and powers of a supervisory committee as prescribed under the Company Law of the People's Republic of China, thereby streamlining the Company's governance structure. The Strategy Committee was also renamed as the Strategy and Sustainability Committee to strengthen sustainability management. At the operational level, the Company formulated a sustainability policy to enhance coordination and implementation.

2026年，公司计划根据《上市公司治理准则》进一步建立健全董事、高级管理人员薪酬管理制度，并将不断跟踪学习监管法规和政策指引，并做好内部制度更新修订。

In 2026, the Company plans to further establish and improve its remuneration management system for Directors and senior management in accordance with the *Code of Corporate Governance of Listed Companies* (《上市公司治理准则》) promulgated by the CSRC. The Company will also continue to monitor regulatory requirements and policy guidelines and update its internal policies as appropriate.

六、强化“关键少数”，加强合规治理

VI. Strengthening Oversight of Key Personnel and Enhancing Compliance Governance

2025 年，公司强化组织公司控股股东和董事、监事、高管等关键少数，通过参加上海证券交易所、新加坡交易所、上市公司协会等组织的任职资格培训、合规治理培训，持续学习法规制度。公司制定并发布《反垄断合规指引》，完善竞争合规管理体系；开发上线“数智合同系统”，统一关键管控节点，建立服务商监管闭环，通过了国家级“营销合规管理体系”认证。

In 2025, the Company strengthened the compliance awareness of its controlling shareholder, Directors, supervisors, senior management and other key personnel by organising their participation in qualification training and compliance governance training conducted by the SSE, the Singapore Exchange Securities Trading Limited, listed company associations and other organisations, and by facilitating their continued learning of applicable laws, regulations and rules. The Company formulated and issued the *Anti-monopoly Compliance Guidelines* (《反垄断合规指引》) to improve its competition compliance management system. It also developed and launched a digital contract management system to standardise key control points and establish a closed-loop management mechanism for service provider supervision. In addition, the Company obtained national-level certification for its marketing compliance management system.

2026 年，公司计划依托拟建立健全的董事、高级管理人员薪酬管理制度，进一步完善对关键少数的激励和监督管理工具。同时，公司将继续组织好关键少数的合规学习工作。

In 2026, the Company plans to further improve its incentive, supervision and management mechanisms for key personnel, with reference to the proposed establishment and improvement of its remuneration management system for Directors and senior management. The Company will also continue to organise compliance training for such key personnel.

公司将持续跟踪评估“提质增效重回报”行动方案的执行情况，践行上市公司责任，回馈广大投资者的支持和关注。

The Company will continue to monitor and evaluate the implementation of its Action Plan for “Quality Improvement, Efficiency Enhancement, and Focus on Shareholder Returns” (“提质增效重回报”), fulfil its responsibilities as a listed company, and deliver value to investors in recognition of their continued support.

本次“提质增效重回报”评估报告与行动方案基于公司目前的实际情况制定，本公告涉及到的前瞻性陈述和战略规划，未来可能会受到宏观政策、行业形势等因素影响，存在一定的不确定性，不构成公司对投资者的实质承诺，敬请广大投资者注意投资风险。

The Evaluation Report on the 2025 Action Plan and the 2026 Action Plan have been prepared based on the Company’s current circumstances. The forward-looking statements and strategic plans contained in this announcement may be affected by factors such as macroeconomic policies and industry conditions and are subject to uncertainties. Such statements and plans do not constitute any representation, undertaking or substantive commitment by the Company to investors. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.